Impact of Valganciclovir Prophylaxis on the Development of Severe Late-Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients
- 20 September 2007
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 39 (7) , 2228-2230
- https://doi.org/10.1016/j.transproceed.2007.07.039
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Immunohistochemically proven cytomegalovirus end‐organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic testsTransplant Infectious Disease, 2007
- Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral ProphylaxisTransplantation, 2006
- Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant RecipientsAmerican Journal of Transplantation, 2006
- Recomendaciones GESITRA-SEIMC y RESITRA sobre prevención y tratamiento de la infección por citomegalovirus en pacientes trasplantadosEnfermedades Infecciosas y Microbiología Clínica, 2005
- Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High-risk CMV D+/R- Transplant RecipientsAmerican Journal of Transplantation, 2005
- Antibody Maturation and Viremia after Primary Cytomegalovirus Infection, in Immunocompetent Patients and Kidney‐Transplant PatientsThe Journal of Infectious Diseases, 2004
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- Cytomegalovirus Disease in High-Risk Transplant Recipients Despite Ganciclovir or Valganciclovir ProphylaxisAmerican Journal of Transplantation, 2003
- Definitions of Cytomegalovirus Infection and Disease in Transplant RecipientsClinical Infectious Diseases, 2002
- Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxisTransplant Infectious Disease, 2000